The Latest Articles from Streetwise Reports


Biotech Could Launch Trial of Polyp Screening Test in March

Research Report
  ()
The start of the C-Scan study would be a major milestone for Check-Cap, noted an H.C. Wainwright & Co. report.

Derm Biopharma Named Top Growth Pick For 2022

Research Report
  ()
Journey Medical should increase 2022 and 2023 revenue by at least 30% such that it could turn a profit in 2024, noted a ROTH Capital Partners report.

This Pharmaceutical Company Has a Brilliant Concept

Contributed Opinion
  ()
Algernon Pharmaceuticals is a clinical-stage, small biotech that boasts a massive pipeline of lower risk and efficient drugs. The company currently has a market cap of US$11.25M, $2M cash in the bank, and several promising late-stage drugs — and it is bound for the NASDAQ. Its closest competitors working on similar illnesses and at similar stages have market caps between $91 and $660 million. Catalysts abound with this genius repurposing company.

Ph1 Trial Results of Dementia Drug Positive

Research Report
  ()
Anavex Life Sciences' study of Anavex 3-71 in frontotemporal dementia met primary and secondary safety endpoints, noted a Dawson James Securities report.

Cell Firm Joins With Food Co. to Create Meat Substitute

Research Report
  ()
Pluristem Therapeutics and Tnuva will incorporate a new company that will use its own funding and resources to develop cell-based synthetic meat products, noted a Dawson James Securities report.

Biotech Co. Partners With Life Sciences Firms

Research Report
  ()
2seventy entered agreements with Novo Nordisk and Genevant to get an in vivo gene editing treatment for hemophilia A developed, noted a Wedbush report.

Enrollment Done for COVID-19 Drug Trial

Research Report
  ()
Part 2 of First Wave BioPharma's RESERVOIR trial of niclosamide to remove the SARS-CoV-2 virus from the GI tract is underway, noted a ROTH Capital Partners report.

2022 to Be Catalyst Rich for Biopharma

Research Report
  ()
The potential stock-moving events for Infinity Pharmaceuticals this year include the launch of two clinical trials and readouts from four studies, noted an H.C. Wainwright & Co. report.

Co.'s samRNA Vaccines Protect Better Against COVID Variants

Research Report
  ()
Gritstone bio Inc.'s lower-dose samRNA vaccines include a broader immune response to SARS-CoV-2 and may provide better protection against emerging variants. BTIG research has issued a "Buy" rating for Gritstone bio.

AI Driven Drug Firm Partners With Merck

  ()
Shares of Absci Corp. rose 18% after the company reported it is collaborating with Merck & Co. to create enzymes using its deep-learning Integrated Drug Creation™ platform and Bionic Protein™ technologies.

Co. Partners to Test New Cancer Vaccines

Research Report
  ()
Genocea Biosciences Inc. is teaming up with Janssen Biotech to explore the immunogenicity of neoantigens and the role and impact of Inhibigens™ in potential vaccine therapies for cancer. H.C. Wainwright & Co. advised that it currently has a "Buy" rating on Genocea.

Medical Co. Strikes $3B Deal to Buy Digital Care Firm

  ()
Shares of Vocera Communications Inc. traded nearly 27% higher after the company reported it entered into a definitive agreement to be acquired by Stryker Corp. for $79.25 per share in cash.

Co. Plans to Make 100M Rapid COVID Tests Monthly

Research Report
  ()
Biopharmaceutical firm Sorrento Therapeutics Inc. plans to mobilize a fully automated assembly line in San Diego, Calif., capable of producing 6 million rapid antigen detection COVISTIX testing units per month starting in Q1/22.

New Muscular Dystrophy Drug Shows Promise

  ()
Edgewise Therapeutics shares traded 24% higher after the company reported its EDG-5506 significantly lowered muscle damage biomarkers in adults after just two weeks of dosing in its Becker muscular dystrophy trial.

Chen Lin's Top 6 Investment Ideas

  ()
In a recent interview with Streetwise Reports, family assets manager and contributing writer, Chen Lin, shared the six (mostly mid-cap) companies that are his top investment picks for 2022.

Lead Cancer Drug Gets Fast Tracked

  ()
Shares of Genprex Inc. traded 165% higher after the company reported the U.S. FDA has awarded Fast Track Designation for its REQORSA™ Immunogene Therapy for use in combination with Merck & Co.'s Keytruda® for non-small cell lung cancer treatment.

Analyst: Drug a 'Hidden Gem for 2022'

Research Report
  ()
Oppenheimer ranks Astria Therapeutics Outperform after learning about its drug for hereditary angioedema, saying "We stay bullish."

Co.'s COVID-19 Test Detects Omicron Variant

Research Report
  ()
H.C. Wainwright & Co. gives Sorrento Therapeutics a Buy rating after initial testing shows its COVISTIX detects COVID-19's Omicron variant.

Co. Still Compelling After Drug Trial Failure

Research Report
  ()
"Arcalyst remains the value driver" for Kiniksa Pharmaceuticals, and "we continue to hold a favorable view of the company," noted a Wedbush report.

Co. Looks To US For Help Fighting Strokes

  ()
Canadian company Algernon Pharmaceuticals Inc. has applied to uplist to the Nasdaq in hopes of attracting U.S. investors to its mission to repurpose drugs.

Co. Rated Outperform As Heart Failure Drug Nears Potential Approval

Research Report
  ()
"Cytokinetics' pipeline of muscle-directed therapies has potential to address several diseases with high unmet medical need and may generate significant revenue across pipeline programs," noted an Oppenheimer report.

Analyst: Question Lingers Over Biotech’s Cell Therapy

Research Report
  ()
A DawsonJames report notes that Brainstorm Cell Therapeutics’ autologous stem cells in amyotrophic lateral sclerosis will need further study to prove their effectiveness.

Coverage Initiated on Biopharma Co. After Turnaround Story

Research Report
  ()
"With Acasti Pharma shares trading near cash levels yet current resources sufficient to achieve key development milestones across the pipeline over 2022-2023, we recommend investors build a position," noted an Oppenheimer report.

Showing Results: 1 to 25 of 150 Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts